AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Scinai Immunotherapeutics Reports Q1 Revenue of $0.59M and $1.02M in Cash and Cash Equivalents as of March 31, 2025.
ByAinvest
Friday, May 30, 2025 10:14 am ET1min read
Scinai Immunotherapeutics reported Q1 revenue of $0.59M, down from previous quarters. The company's cash and cash equivalents and short-term deposits decreased to $1.02M as of March 31, 2025, from $1.96M in March 2024.
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) reported its financial results for the first quarter of 2025, revealing a decrease in revenue and a significant reduction in cash reserves. The company's revenue for the quarter ended March 31, 2025, totaled $586,000, down from the previous quarters. This decrease is attributed to lower wages and reduced direct research and development (R&D) expenses, which amounted to $1,296,000 for the quarter, compared to $1,568,000 in the same period last year [1].The company's cash and cash equivalents and short-term deposits decreased to $1,018,000 as of March 31, 2025, from $1,964,000 in March 2024. This reduction is primarily due to the company's ongoing R&D activities and the conversion of the European Investment Bank (EIB) loan into preferred shares of the Company stock in the third quarter of 2024 [1].
Scinai's CDMO unit, which began generating revenues in the second quarter of 2024, contributed to the company's overall revenue. The CDMO business showed year-over-year growth, with revenues increasing to $586,000 in Q1 2025 from $658,000 in 2024 [1].
The company reported a net loss of $1,557,000 for the quarter, compared to a net loss of $2,159,000 in the same period last year. The improvement in net loss was primarily due to lower R&D expenses, reduced financial expenses, and the recognition of gross income [1].
Scinai's financial results for Q1 2025 indicate a challenging period for the company, with significant reductions in cash reserves and revenue. However, the company's CDMO unit continues to show growth potential. Investors should closely monitor Scinai's future financial performance and the progress of its R&D activities.
References:
[1] https://finance.yahoo.com/news/scinai-reports-q1-2025-financial-110000195.html
[2] https://seekingalpha.com/news/4453900-scinai-immunotherapeutics-reports-q1-results
[3] https://www.morningstar.com/news/pr-newswire/20250530ln99650/scinai-reports-q1-2025-financial-results-highlighting-strong-cdmo-revenue-momentum-and-reduced-cash-burn
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet